Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Curve vs KERNX Health

Curve
Graded #289

Lower grade

vs+0.19999999999999574
KERNX Health
Graded #282

Higher grade

The verdict

KERNX Health takes it — 61.9/100 to 61.7/100, but only just.

KERNX Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Washington DC telehealth platform selling compounded semaglutide and tirzepatide on flat monthly plans, with the physician consultation billed separately per visit. Curve is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueKERNX Health +4
57
61
Dose & formulationEven
64
64
Clinical oversightKERNX Health +3
68
71
Labs & monitoringEven
52
52
FulfillmentCurve +28
97
69
Contract termsKERNX Health +25
20
45
Curve · left barKERNX Health · right bar

The numbers

MetricCurveKERNX Health
WeighScore61.7/10061.9/100
GradeCC
Scorecard rank#289#282
Semaglutide$175/mo (compounded)$129/mo (promotional rate, plus a separate fee, compounded)
Tirzepatide$225/mo (compounded)$199/mo (promotional rate, plus a separate fee, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Curve

Graded #289 · C

Strengths

  • Offers both compounded semaglutide and tirzepatide, with every dose priced the same so cost does not rise as you titrate up.
  • LegitScript-certified (seal #51079066) and names both its 503A compounding pharmacy, VialsRx, and its provider network, Beluga Health.
  • Transparent tiered pricing with a real month-to-month option; consultation, medication, and free expedited shipping included, no membership.
  • Available in all 50 states with same-day provider review; no insurance needed and HSA/FSA accepted.

Where it loses points

  • Very new (2026 launch) with a thin track record; the site still shows a Webflow template credit and a leftover Cora reference in its Terms.
  • The cheapest headline rates ($99 semaglutide / $135 tirzepatide) require a 12-month prepay; true month-to-month is $175 and $225.
  • Both product pages currently display an out-of-stock status, so availability may be inconsistent.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.
KERNX Health

Graded #282 · C

Strengths

  • Publishes plan pricing openly, before any intake or account creation
  • Month-to-month with no long-term contract and no multi-month prepayment
  • Billing starts only after a licensed provider approves treatment
  • LegitScript certification verified against the issued seal, not just the badge

Where it loses points

  • Its own pricing page contradicts itself: it claims no separate consultation charges, then states a $25-$60 fee applies per visit
  • The consultation fee is charged whether or not a prescription is issued
  • Advertised $129 and $199 rates are time-limited founding rates; standard rates are $249 and $299
  • No compounding pharmacy is named anywhere on the site
  • Shipping claims conflict: a 48-hour figure on the homepage against 1-2 days to ship plus 2-3 days transit in the FAQ

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard